2m 2m 2m 2m 2m 2m 2m
RECURSN PHARMA-A (RXRX)
NASDAQ
$3.16-$0.03 (-0.79%)
Price as of Jun 23, 2026 7:58 PM EDT- $1.7BMarket Cap
- -34.16%1-Year Change
- BiotechnologyIndustry
RECURSN PHARMA-A (RXRX)
$3.16-$0.03 (-0.79%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 74.3M +26.20% | 58.8M +32.00% | 44.6M +11.88% | 39.8M +291.46% | |
Cost of Revenue | 71.0M +56.84% | 45.2M +6.22% | 42.6M -11.78% | 48.3M N/A | |
Gross Profit | 3.3M -75.72% | 13.6M +584.15% | 2.0M +123.58% | -8.4M -182.85% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -475.3M +51.16% | -314.4M +30.34% | -241.2M +54.93% | -155.7M +15.10% | |
Depreciation and Amortization Expense | 83.7M +129.36% | 36.5M +49.55% | 24.4M +107.57% | 11.8M +39.87% | |
Total Operating Expenses | 722.8M +34.39% | 537.8M +36.29% | 394.6M +38.19% | 285.6M +48.00% | |
Operating Profit | -648.1M +35.31% | -479.0M +36.83% | -350.1M +42.46% | -245.7M +34.44% | |
Interest Income | 22.8M +44.61% | 15.8M -17.57% | 19.1M +205.66% | 6.3M +8,467.12% | |
Interest Expense | N/A N/A | N/A N/A | -97,000 +76.36% | -55,000 -98.14% | |
Interest Income and Expense and Net | 22.8M +44.61% | 15.8M -17.15% | 19.0M +206.81% | 6.2M +315.32% | |
Total Nonoperating Income and Expense | 3.2M -77.23% | 14.2M -20.72% | 17.9M +186.87% | 6.3M +268.76% | |
Income before Taxes | -644.9M +38.75% | -464.8M +39.94% | -332.1M +35.16% | -245.7M +34.44% | |
Income Taxes | -136,000 -87.93% | -1.1M -72.26% | -4.1M N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -644.8M +39.06% | -463.7M +41.33% | -328.1M +36.99% | -239.5M +28.42% | |
Net Income from Continuing Operations Applicable to Common | -644.9M +38.75% | -464.8M +39.94% | -332.1M +38.69% | -239.5M +28.42% | |
Basic EPS and Net Income | -1.44 -14.79% | -1.69 +6.96% | -1.58 +16.18% | -1.36 -8.72% | |
Diluted EPS and Net Income | -1.44 -14.79% | -1.69 +6.96% | -1.58 +16.18% | -1.36 -8.72% | |
Basic Weighted Average Shares | 447.4M +63.18% | 274.2M +31.92% | 207.9M +18.41% | 175.5M +40.04% | |
Diluted Weighted Average Shares | 447.4M +63.18% | 274.2M +31.92% | 207.9M +18.41% | 175.5M +40.04% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 743.3M +25.06% | 594.4M +51.79% | 391.6M -28.79% | 549.9M +92.87% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Cash and Cash Equivalents and Short-Term Investments | 743.3M +25.06% | 594.4M +51.79% | 391.6M -28.79% | 549.9M +6.46% | |
Total Current Assets | 812.8M +13.80% | 714.3M +63.02% | 438.1M -23.11% | 569.8M +6.56% | |
Accumulated Depreciation | 89.2M +42.35% | 62.7M +39.67% | 44.9M +49.00% | 30.1M +60.72% | |
Property and Plant and Equipment and Net | 103.9M -26.32% | 141.1M +63.06% | 86.5M -1.91% | 88.2M +36.26% | |
Total Long-Term Assets | 12.8M +44.52% | 8.8M +3,281.23% | 261,000 N/A | 0 -100.00% | |
Total Assets | 1.5B +1.76% | 1.4B +121.60% | 653.7M -6.79% | 701.3M +14.90% | |
Income Taxes Payable | 23.3M +40.30% | 16.6M +1,137.86% | 1.3M N/A | N/A N/A | |
Total Short-Term Debt | 9.1M +7.91% | 8.4M +20,448.78% | 41,000 -57.73% | 97,000 +7.78% | |
Total Current Liabilities | 147.7M -21.21% | 187.5M +101.21% | 93.2M -7.08% | 100.3M +114.89% | |
Total Long-Term Debt | 9.6M -49.72% | 19.0M +1,627.70% | 1.1M +105.41% | 536,000 -15.32% | |
Total Long-Term Liabilities | 2.1M -56.04% | 4.7M -95.19% | 98.4M -14.57% | 115.2M +909.79% | |
Total Liabilities | 343.3M -17.05% | 413.8M +117.50% | 190.3M -11.70% | 215.5M +219.67% | |
Retained Earnings | -2.1B +45.04% | -1.4B +47.92% | -967.6M +51.30% | -639.6M +59.86% | |
Total Stockholders Equity | 1.1B +9.29% | 1.0B +123.28% | 463.4M -4.60% | 485.8M -10.52% | |
Total Shares Outstanding | 528.2M +33.11% | 396.8M +69.38% | 234.3M +22.64% | 191.0M +12.19% | |
Cash Flow | |||||
Cash from Operating Activities | -371.8M +3.52% | -359.2M +24.81% | -287.8M +244.55% | -83.5M -47.34% | |
Capital Expenditures | 6.5M -52.76% | 13.7M +14.55% | 12.0M -67.74% | 37.1M -6.88% | |
Cash from Investing Activities | -16.9M -106.49% | 260.1M +2,642.62% | -10.2M -105.29% | 193.2M +171.11% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 521.5M +71.49% | 304.1M +117.02% | 140.1M -9.21% | 154.3M -66.34% | |
Financials Ratio | |||||
Gross Margin | 4.45% -80.76% | 23.12% +418.30% | 4.46% +121.07% | -21.16% N/A | |
Operating Margin | -872.83% +7.22% | -814.09% +3.66% | -785.33% +27.34% | -616.74% N/A | |
Return on Assets | -44.12% +0.02% | -44.11% -8.91% | -48.42% +32.61% | -36.52% N/A | |
Return on Equity | -59.54% -3.80% | -61.89% -10.46% | -69.12% +48.47% | -46.56% N/A | |
Revenue Growth | 26.20% -18.12% | 32.00% +169.44% | 11.88% -95.93% | 291.46% N/A | |
Current Ratio | 5.50 +44.44% | 3.81 -18.98% | 4.70 -17.25% | 5.68 N/A | |
Cash Ratio | 5.03 +58.73% | 3.17 -24.56% | 4.20 -23.37% | 5.48 N/A | |
Debt-to-Equity Ratio | 0.02 -37.74% | 0.03 +960.00% | 0.003 +92.31% | 0.001 N/A | |
Debt-to-Assets Ratio | 0.01 -32.80% | 0.02 +1,011.76% | 0.002 +88.89% | 0.0009 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow